Status:
NOT_YET_RECRUITING
A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis
Lead Sponsor:
Keymed Biosciences Co.Ltd
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This is a multi-center, open-label phase 2 study to evaluate the long-term safety and efficacy of CM310 in subjects with moderate-to-severe atopic dermatitis.
Detailed Description
The study consists of an screening period, treatment period, and safety follow-up period.
Eligibility Criteria
Inclusion
- Have the ability to understand the study and voluntarily sign a written informed consent form (ICF).
- Age ≥ 18 and ≤ 75 years old.
- With Atopic Dermatitis.
Exclusion
- Not enough washing-out period for previous therapy.
- Concurrent disease/status which may potentially affect the efficacy/safety judgement.
- Major surgeries are planned during the study period.
Key Trial Info
Start Date :
March 30 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 30 2026
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06116565
Start Date
March 30 2024
End Date
March 30 2026
Last Update
November 3 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.